2 volunteers were eligible. Titles and abstracts were reviewed by at least 2 authors, and potentially relevant studies underwent full text review. Discrepancies in study selection were resolved by consensus.
Data Extraction and Synthesis
Three authors independently extracted data, using a standardized data extraction form.
Discrepancies in extracted data were resolved by consensus. Studies were assessed as low, unclear, or high risk of bias in each of 6 domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, and selective reporting. Data reported on a 100-point visual analog scale (VAS) were reported as mean difference.
When data were measured with different scales, they were combined with standardized mean difference.
A fixed-effect model was used when the I2 statistic was less than 40%; otherwise, a random-effects model was used.
Results
The search identified 2,110 titles, of which 9 met the inclusion criteria and were included in the review. Eight of these (N=848) were included in the meta-analysis. Six studies were conducted in the emergency department (ED), and 3 studies were of children. Four of the studies were blinded, and the overall quality of the evidence was rated as moderate to high. Vapocoolants modestly reduced pain on a 100-point VAS (Table) . I2 was 74%, indicating a high degree of heterogeneity. Sensitivity analyses based on risk of bias, setting (ED versus other), children versus adults, type of vapocoolant, and duration of vapocoolant application did not yield significant differences and did not explain the heterogeneity. Only 2 studies provided dichotomized data by pain relief (yes/no), which suggested that vapocoolant spray had increased odds of relieving pain. The overall summary results based on meta-analysis found that vapocoolants provide pain relief during cannulation (Table) ; however, pain increased slightly with vapocoolant application. Vapocoolant use did not affect first-attempt success of intravenous cannulation.
Commentary
Intravenous cannulation is one of the most common painful procedures performed in the ED. This study demonstrated a small decrease in procedural pain, with no difference in cannulation success; however, the clinical significance of the difference must be questioned. The often-cited difference in pain measured on a 100-point VAS that is clinically relevant is 13.6, 7 This study demonstrated a decrease in the point estimate of 12.5, which is just below this clinically relevant threshold, and the 95% confidence interval extended down to a difference of only 6.4 points.
Additionally, the application of the spray increased pain by a mean of 6.3 on the VAS. Therefore, we cannot say with confidence that the effect is clinically important. The substantial heterogeneity among the trials further decreases confidence in the overall estimate of effect.
There were several additional limitations to this systematic review. Most studies were performed with adults, whereas vapocoolant is more commonly used for children. Half of the included studies did not quantify differences in intravenous cannula size, which can affect the pain of insertion. Four studies did not blind the participants or assessors and only 4 studies used a sham spray, so it is difficult to 4 determine the magnitude of any placebo effect. There was also no assessment of baseline difficulty of intravenous access. Overall, there was an 83% first attempt success rate for cannulation, suggesting that these patients were not difficult intravenous catheter insertions. Given the potential of cold to induce vasoconstriction, it is unclear whether this treatment will decrease success rates in patients with more difficult intravenous access.
The use of vapocoolants did appear to be safe; reported adverse events were minor and included 4 reports of cold sensitivity, 3 transient reactions of erythema at the site, and 1 report of burning sensation.
Although there was a small increase in pain associated with the application of the vapocoolant spray (Table) , this also was of questionable clinical significance.6, 7 Although there were no major complications observed, health care providers should be aware that, rarely, prolonged spraying can cause skin hypopigmentation and atrophic scarring, especially in patients with poor circulation.8 Finally, one must consider the initial rationale for placing the intravenous catheter. Studies have demonstrated that 50% of intravenous catheters placed in the ED were never used9; therefore, the best way to mitigate the pain associated with catheter placement is to not place it when it is unnecessary. 
